用STING辅助的外膜囊泡纳米颗粒疫苗对抗Pseudomonas aeruginosa
Elisabet Bjånes1, Nishta Krishnan2, Truman Koh1
1Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California San Diego, La Jolla, United States of America.
JCI insight
|July 24, 2025
概括
一个新的纳米技术疫苗平台将细菌外膜囊泡与激活STING的纳米核相结合. 这种细胞纳米粒子候选疫苗 (CNP) 在临床前模型中成功地保护了Pseudomonas aeruginosa肺炎.
科学领域:
- 免疫学 免疫学 免疫学
- 纳米技术纳米技术
- 微生物学 微生物学
背景情况:
- 耐多药性细菌性肺炎,特别是来自Pseudomonas aeruginosa,是一个重大的全球健康问题.
- 来自格拉姆阴性细菌的外膜囊泡 (OMV) 是免疫原的,但在疫苗开发中面临稳定性挑战.
- 对高优先级的多药耐药病原体进行有效疫苗的急需非常大.
研究的目的:
- 使用纳米技术开发一种针对Pseudomonas aeruginosa的新型疫苗平台.
- 通过将OMVs与辅助剂装载核心相结合,创建一种细菌细胞纳米粒子疫苗候选物 (CNP).
- 为了评估Pa-STING-CNP疫苗的免疫性和保护功效.
主要方法:
- 开发了一种新型的疫苗平台,通过将免疫外膜囊泡 (OMVs) 涂在自助剂STING (干扰素基因刺激器) 纳米核上,创建Pa-STING-CNP.
- 在临床前模型中使用Pa-STING-CNP候选疫苗.
- 评估了抗原呈现细胞的招募和激活,抗体反应,以及对Pseudomonas aeruginosa致命挑战的保护.
主要成果:
- 接种Pa-STING-CNP疫苗诱导了在排水淋巴结中显著的抗原呈现细胞的招募和激活.
- 在接种疫苗后观察到强大的抗伪蒙斯抗体反应.
- 该疫苗对高毒性P. aeruginosa菌株 (PA14) 的致命挑战提供了显著的保护,抗体对异种菌株 (PA01) 提供了被动免疫力.
结论:
- 纳米技术可以被利用来创建一个稳定和有效的疫苗平台来对抗具有挑战性的多抗药性病原体,如Pseudomonas aeruginosa.
- 该Pa-STING-CNP候选疫苗显示出作为预防P. aeruginosa相关肺炎的高度有效解决方案的潜力.
- 这种方法强调了将细菌成分与先进的纳米技术结合为下一代疫苗的承诺.
更多相关视频
相关概念视频
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...